Skip to main content
Journal cover image

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Publication ,  Journal Article
Luo, X; Herold, KC; Miller, SD
Published in: Immunity
April 23, 2010

Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing pancreatic beta cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory therapies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Looking forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies, including tolerance induced by "tolerogenic" antigen-presenting cells pulsed with diabetogenic antigens and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process, antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-producing beta cells from endogenous progenitors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Immunity

DOI

EISSN

1097-4180

Publication Date

April 23, 2010

Volume

32

Issue

4

Start / End Page

488 / 499

Location

United States

Related Subject Headings

  • Immunotherapy
  • Immunology
  • Immune Tolerance
  • Humans
  • Diabetes Mellitus, Type 1
  • Antigen-Presenting Cells
  • Antibodies
  • Animals
  • 3204 Immunology
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Luo, X., Herold, K. C., & Miller, S. D. (2010). Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity, 32(4), 488–499. https://doi.org/10.1016/j.immuni.2010.04.002
Luo, Xunrong, Kevan C. Herold, and Stephen D. Miller. “Immunotherapy of type 1 diabetes: where are we and where should we be going?Immunity 32, no. 4 (April 23, 2010): 488–99. https://doi.org/10.1016/j.immuni.2010.04.002.
Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 2010 Apr 23;32(4):488–99.
Luo, Xunrong, et al. “Immunotherapy of type 1 diabetes: where are we and where should we be going?Immunity, vol. 32, no. 4, Apr. 2010, pp. 488–99. Pubmed, doi:10.1016/j.immuni.2010.04.002.
Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity. 2010 Apr 23;32(4):488–499.
Journal cover image

Published In

Immunity

DOI

EISSN

1097-4180

Publication Date

April 23, 2010

Volume

32

Issue

4

Start / End Page

488 / 499

Location

United States

Related Subject Headings

  • Immunotherapy
  • Immunology
  • Immune Tolerance
  • Humans
  • Diabetes Mellitus, Type 1
  • Antigen-Presenting Cells
  • Antibodies
  • Animals
  • 3204 Immunology
  • 1107 Immunology